Prospects for gene therapy in inherited neurodegenerative diseases

被引:17
作者
Cardone, Monica [1 ]
机构
[1] TIGEM, I-80131 Naples, Italy
关键词
central nervous system; gene therapy; neurodegenerative disease; viral vector;
D O I
10.1097/WCO.0b013e32809f97ff
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Purpose of review The use of gene therapy to correct or replace deficient genes has been a long standing aspiration. Recent findings Recent findings from basic and applied research suggest that at last it may be possible to translate experimental procedures into effective patient therapies for genetic diseases. Therapies for neurodegenerative diseases potentially include, as their targets, both monogenic conditions (e.g. lysosomal storage disorders) and more genetically complex diseases (such as Alzheimer's and Parkinson's disorders). Summary The use of gene therapy to target the central nervous system presents specific technical and biological challenges. These may be overcome by using novel gene vector delivery strategies. Current research should illuminate the temporal window required to achieve a successful therapy. As greater knowledge is accumulated about gene therapy, correlations will be made between the level of gene expression from the therapeutic vector, the extent of correction after treatment, and the stage of disease progression when therapy is initiated.
引用
收藏
页码:151 / 158
页数:8
相关论文
共 65 条
[1]   Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC [J].
Bankiewicz, Krystof S. ;
Forsayeth, John ;
Eberling, Jamie L. ;
Sanchez-Pernaute, Rosario ;
Pivirotto, Philip ;
Bringas, John ;
Herscovitch, Peter ;
Carson, Richard E. ;
Eckelman, William ;
Reutter, Bryan ;
Cunningham, Janet .
MOLECULAR THERAPY, 2006, 14 (04) :564-570
[2]   Convection-enhanced delivery of AAV vector in parkinsonian monkeys;: In vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach [J].
Bankiewicz, KS ;
Eberling, JL ;
Kohutnicka, M ;
Jagust, W ;
Pivirotto, P ;
Bringas, J ;
Cunningham, J ;
Budinger, TF ;
Harvey-White, J .
EXPERIMENTAL NEUROLOGY, 2000, 164 (01) :2-14
[3]   THE CHOLINERGIC HYPOTHESIS OF GERIATRIC MEMORY DYSFUNCTION [J].
BARTUS, RT ;
DEAN, RL ;
BEER, B ;
LIPPA, AS .
SCIENCE, 1982, 217 (4558) :408-417
[4]   Lentiviral vectors as a gene delivery system in the mouse midbrain:: Cellular and behavioral improvements in a 6-OHDA model of Parkinson's disease using GDNF [J].
Bensadoun, JC ;
Déglon, N ;
Tseng, JL ;
Ridet, JL ;
Zurn, AD ;
Aebischer, P .
EXPERIMENTAL NEUROLOGY, 2000, 164 (01) :15-24
[5]   Long-term and significant correction of brain lesions in adult mucopolysaccharidosis type VII mice using recombinant AAV vectors [J].
Bosch, A ;
Perret, E ;
Desmaris, N ;
Heard, JM .
MOLECULAR THERAPY, 2000, 1 (01) :63-70
[6]   Functional reinnervation from remaining DA terminals induced by GDNF lentivirus in a rat model of early Parkinson's disease [J].
Brizard, M ;
Carcenac, C ;
Bemelmans, AP ;
Feuerstein, C ;
Mallet, J ;
Savasta, M .
NEUROBIOLOGY OF DISEASE, 2006, 21 (01) :90-101
[7]   Adeno-associated virus vectors serotyped with AAV8 capsid are more efficient than AAV-1 or-2 serotypes for widespread gene delivery to the neonatal mouse brain [J].
Broekman, MLD ;
Comer, LA ;
Hyman, BT ;
Siena-Esteves, M .
NEUROSCIENCE, 2006, 138 (02) :501-510
[8]   Correction of Hunter syndrome in the MPSII mouse model by AAV2/8-mediated gene delivery [J].
Cardone, M ;
Polito, VA ;
Pepe, S ;
Mann, L ;
D'Azzo, A ;
Auricchio, A ;
Ballabio, A ;
Cosma, MP .
HUMAN MOLECULAR GENETICS, 2006, 15 (07) :1225-1236
[9]   Adeno-associated virus vectors in clinical trials [J].
Carter, BJ .
HUMAN GENE THERAPY, 2005, 16 (05) :541-550
[10]   α-L-Iduronidase transport in neurites [J].
Chen, FT ;
Vitry, S ;
Hocquemiller, M ;
Desmaris, N ;
Ausseil, J ;
Heard, JM .
MOLECULAR GENETICS AND METABOLISM, 2006, 87 (04) :349-358